Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients

Transplant Infectious Disease

Volumn 2, Issue 1, 2000, Pages 15-21

  Turgeon, N ^a   Hovingh, G K ^a   Fishman, J A ^a   Basgoz, N ^a   Tolkoff Rubin, N E ^a   Doran, M ^a   Cosimi, A B ^a   Rubin, R H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Antilymphocyte antibody therapy; Cytomegalovirus; Granulocyte colony stimulating factor; Kidney transplant; Liver transplant

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BTI 122; CD2 ANTIGEN; CYCLOSPORIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME;

EID: 0034062033     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2000.020104.x     Document Type: Article

References (25)

1. RUBIN RH. Infection in the organ transplant recipient. In: RUBIN RH, YOUNG LS, eds. Clinical Approach to Infection in the Compromised Host. (3rd edn.) New York: Plenum, 1994: 629-705.
2. LIESCHKE GJ, BURGESS AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. (First of two parts) N Engl J Med 1992: 327: 28-35.
3. LIESCHKE GJ, BURGESS AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. (Second of two parts) N Engl J Med 1992: 327: 99-106.
4. LINDEMANN A, HEREMANN F, OSTER W, et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989: 74: 2644-2651.
5. HARTMANN LC, TSCHETTER LK, HABERMANN TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997: 336: 1776-1780.
6. TAJIMA A, ASO Y, KAWABE K, et al. Colony-stimulating factor for treatment of leukopenia after kidney allografting. Transplant Proc 1991: 23: 1369-1370.
7. COLQUHOUN SDB, SHAKED A, JURIM O, et al. Reversal of neutropenia with granulocyte colony-stimulating factor without precipitating liver allograft rejection. Transplantation 1993: 56: 1593-1595.
8. MORIN MP, MAMZER MF, et al. Use of granulocyte-macrophage colony-stimulating factor in leukopenic renal transplant recipient. Transplant Proc 1994: 26: 283.
9. SQUIERS EC, ELKHAMMAS EA, HENRY ML. Use of granulocyte-macrophage colony-stimulating factor for reversal of neutropenia following combined kidney-pancreas transplantation. Transplant Proc 1995: 27: 3092-3093.
10. FOSTER PF, MITAL D, SANKARY HN, et al. The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 1995: 59: 1557-1563.
11. PEDDI VR, HARIHARAN S, SCHROEDER TJ, FIRST MR. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Clin Transplant 1996: 10: 20-23.
12. DELMONICO FL, TOLKOKF-RUBIN NE, AUCHINCLOSS H JR, et al. Management of the renal allograft recipient: immunosuppressive protocols for long-term success. Clin Transplant 1994: 8: 34-39.
13. GILBERT JR, PASCUAL M, SCHOENFELD DA, et al. Evolving trends in liver transplantation: an outcome and charge analysis. Transplantation 1999: 67: 246-253.
14. MAZZULLI T, RUBIN RH, FERRARO MJ, et al. Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in patients with AIDS. J Clin Microbiol 1993: 31: 2824-2927.
15. DANKNER WM, SCHOLL D, STANAT SC, et al. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J Virol Methods 1990: 28: 293-298.
16. RUBIN RH, FISHMAN JA, TOLKOFF-RUBIN NE, et al. The effectiveness of intravenous followed by oral ganciclovir in the prevention of primary cytomegalovirus disease in organ transplant recipients. To be published.
17. TURGEON N, FISHMAN JA, BASGOZ N, et al. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 1998: 66: 1780-1786.
18. OZER H. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors. Curr Opin Hematol 1996: 3: 3-10.
19. MINGUEZ C, MAZUECOS A, CEBALLOS A, et al. Worsening of renal function in a renal transplant patient treated with granulocyte colony-stimulating factor. (Letter) Nephrol Dial Transplant 1995: 10: 2166-2167.
20. FOSTER PF, KOCISS K, SHEN J, et al. Granulocyte colony-stimulating factor immunomodulation in the rat cardiac transplantation model. Transplantation 1996: 61: 1122-1125.
21. SIMMONS P, KAUSHANSKY K, TOROK-STORB B. Mechanisms of cytomegalovirus-mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci USA 1990: 87: 1386-1390.
22. MAYER A, PODLECH J, KURZ S, et al. Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes. J Virol 1997: 71: 4589-4598.
23. SOMMADOSSI JP, CARLISLE R. Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother 1987: 31: 452-454.
24. KUTSOGIANNIS DJ, CROWTHER MA, LAZAROVITS AI. Granulocyte macrophage colony-stimulating factor for the therapy of cytomegalovirus and ganciclovir-induced leukopenia in a renal transplant recipient. Transplantation 1992: 53: 930-932.
25. PATEL HD, ANDERSON JR, DUNCOMBE AS, et al. Granulocyte colony-stimulating factor. A new application for cytomegalovirus-induced neutropenia in cardiac allograft recipients. Transplantation 1994: 58: 863-867.